Faricimab news

All news on Faricimab (also known as Vabysmo): plants, production capacities, investments and involved companies.

30 April 2026

Roche to present ophthalmology portfolio data at ARVO 2026

ARVO 2026: real‑world data show Vabysmo reduces retinal fluid in nAMD/DME; Susvimo enables sustained delivery with lower treatment burden; early vamikibart IL‑6 results; 45+ abstracts.
29 April 2026

Genentech to present ophthalmology data at ARVO 2026

ARVO presentations: real-world Vabysmo data show retinal drying in wet AMD/DME; Susvimo demonstrates sustained delivery and reduced treatment burden; vamikibart shows early efficacy; >45 abstracts
29 January 2026

Roche Reports 7% Sales Growth in 2025 Results

Pharmaceuticals and diagnostics drive profit and earnings growth. Key approvals and advancements in therapies. Dividend increase proposed. Board changes announced. Positive 2026 outlook.
17 October 2025

Roche Unveils Phase III Data for Vamikibart in Uveitic Macular Edema

Vamikibart shows promise in treating UME, with significant vision improvements in trials, offering a non-steroid alternative with fewer side effects.

Who will be producing Faricimab in the future?

Find out with chemXplore Alpha

Learn more